[Drug committees welcome the SBU hypertension report. A number of patients can be offered cost-effective, evidence-based therapy].
作者信息
Ohlsson Ola
机构信息
Medicinska kliniken, Centralsjukhuset, Kristianstad.
出版信息
Lakartidningen. 2004 Dec 2;101(49):3984-5.
PMID:15633336
Abstract
摘要
相似文献
1
2
Considerations in the treatment of mild-to-moderate hypertension.
Manag Care Interface. 2001 Mar;14(3):80-1.
3
[The double messages about atenolol must be an issue for the SBU board].[关于阿替洛尔的双重信息必定是战略业务单元董事会要考虑的一个问题]。
Lakartidningen. 2004 Dec 2;101(49):4038, 4041; discussion 4041-2, 4045.
4
Out-of-pocket costs to users: medicine options for hypertension.用户自付费用：高血压的药物选择
Am J Hypertens. 2008 May;21(5):492. doi: 10.1038/ajh.2008.150.
5
[Selection criteria in the treatment of arterial hypertension and recommended guidelines].[动脉高血压治疗的选择标准及推荐指南]
Cardiologia. 1999 Dec;44 Suppl 1(Pt 2):527-32.
6
Discrepancies between use of antihypertensive drugs and guidelines indications: pharmacoeconomic implications.抗高血压药物使用与指南适应症之间的差异：药物经济学影响。
J Hum Hypertens. 2005 Oct;19(10):819-22. doi: 10.1038/sj.jhh.1001900.
7
Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.ASCOT-BPLA的经济学评估：与基于阿替洛尔的治疗方案相比，基于氨氯地平的降压治疗方案具有成本效益。
Heart. 2008 Feb;94(2):e4. doi: 10.1136/hrt.2007.127217. Epub 2007 Oct 4.
8
[Medical economics of hypertension therapy].[高血压治疗的医学经济学]
Nihon Rinsho. 2008 Aug;66(8):1601-4.
9
[Comment on IOWiG report plan. A medical decision may not be replaced].[关于IOWiG报告计划的评论。医疗决策不可替代]
MMW Fortschr Med. 2006 May 11;148(19):42.
10
An economic evaluation of the 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of mild-to-moderate hypertension in Greece.2003年欧洲高血压学会-欧洲心脏病学会希腊轻度至中度高血压管理指南的经济学评估。
Am J Hypertens. 2005 Sep;18(9 Pt 1):1233-40; discussion 1241-2. doi: 10.1016/j.amjhyper.2005.05.001.
Zotero 插件